Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (CUTNRUN)

ABSTRACT: Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (CUTNRUN)

PROVIDER: PRJNA907327 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22486248_1.fastq.gz	Fastqsanger.gz
	SRR22486248_2.fastq.gz	Fastqsanger.gz
	SRR22486249_1.fastq.gz	Fastqsanger.gz
	SRR22486249_2.fastq.gz	Fastqsanger.gz
	SRR22486250_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 64

Similar Datasets

Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction

Project description:Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction

| PRJNA907320 | ENA

Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (RNA-Seq)

Project description:Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (RNA-Seq)

| PRJNA907325 | ENA

Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (ATAC-Seq I)

Project description:Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (ATAC-Seq I)

| PRJNA907322 | ENA

Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (ATAC-Seq II)

Project description:Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (ATAC-Seq II)

| PRJNA907323 | ENA

Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (CUTNRUN)

Project description:We show that across human and/or mouse tumors immune dysfunction is associated with cancer cells acquiring epigenetic features of inflammatory memory. Here, inflammatory memory domains, many of which are initiated by chronic IFNG, are established by STAT1 and IRF3 and link H3K4me1-marked chromatin accessibility to increased expression of a subset of IFN-stimulated genes (ISGs).

2022-12-08 | GSE219178 | GEO

XBP1s cutnrun

Project description:XBP1s cutnrun

| PRJNA949270 | ENA

XBP1s cutnrun

Project description:XBP1s cutnrun

| PRJNA887070 | ENA

Tumour mtDNA mutations drive aerobic glycolysis to enhance checkpoint blockade

Project description:Mitochondrial DNA (mtDNA) encodes essential machinery for respiration and metabolic homeostasis but is paradoxically among the most common targets of somatic mutations in the cancer genome, with truncating mutations in complex I genes being over-represented1 . While mtDNA mutations have been associated with both improved and worsened prognoses in several cancer lineages1–3, whether these mutations are drivers, or exert any functional effect on tumour biology remains controversial. Here we discover that complex I-encoding mtDNA mutations are sufficient to remodel the tumour immune landscape and therapeutic resistance to immune checkpoint blockade. Using mtDNA base editing technology we engineered recurrent truncating mutations in the mtDNA-encoded complex I gene, Mt-Nd5, into murine models of melanoma. Mechanistically, these mutations promoted utilisation of pyruvate as a terminal electron acceptor and increased glycolytic flux driven by an over-reduced NAD pool and NADH shuttling between GAPDH and MDH1, mediating a Warburg-like metabolic shift. In turn, without modifying tumour growth, this altered cancer cell-intrinsic metabolism reshaped the tumour microenvironment of mouse and human cancer in a mutation load-dependent fashion, encouraging an anti-tumour immune response. This subsequently sensitises both mouse and human cancers with high mtDNA mutant heteroplasmy to immune checkpoint blockade. Strikingly, patient lesions bearing >50% mtDNA mutation load demonstrated a >2.5-fold improved response rate to checkpoint inhibitor blockade. Taken together these data nominate mtDNA mutations as functional regulators of cancer metabolism and tumour biology, with potential for therapeutic exploitation and treatment stratification.

2023-11-08 | PXD039705 | Pride

Tumour mtDNA mutations drive aerobic glycolysis to enhance checkpoint blockade (part 2)

2023-11-08 | PXD044987 | Pride

Melanoma Sequential Immune Checkpoint Blockade Treatment Sequencing Study

Project description:Melanoma Sequential Immune Checkpoint Blockade Treatment Sequencing Study

| PRJNA397812 | ENA